Sign in Subscribe
Cancer research

Breakthrough in Prostate Cancer Research: Novel Cell Line Model and Potential Therapeutic Target

Strategic Insights

— 1 min read

Investigators at the Sunnybrook Research Institute in Toronto, Canada, have published a groundbreaking study on prostate cancer, developing a novel primary cell line model of localized prostate cancer and radioresistance. The research aimed to address the mechanisms of therapy resistance and identify potential therapeutic targets for sensitizing radioresistant disease. The study highlights the significance of nicotinamide N-methyltransferase (NNMT) as a potential therapeutic target for radiosensitizing prostate cancer cells.

Key Takeaways:

  • Researchers at the Sunnybrook Research Institute developed a novel primary cell line model of localized prostate cancer, designated CaB34, which spontaneously immortalized and was used to generate a paired radioresistant subline, CaB34-CF.
  • Multi-omic analyses identified NNMT as the most significantly dysregulated component in CaB34-CF, suggesting its role in tumor progression.
  • Knockdown studies of NNMT demonstrated significant radiosensitization of CaB34-CF cells, which was largely due to increased radiation-induced cellular senescence.
  • Growth as 3D organoids was significantly higher in the CaB34-CF line, and demonstrated a less structured pattern of expression of cytokeratin markers.
  • Radiosensitization with NNMT siRNA was recapitulated in a 3D organoid clonogenic assay in CaB34-CF cells.
  • The research has the potential to improve the treatment of prostate cancer, particularly in cases where the disease has become radioresistant.

Statistics:

  • Prostate cancer is the second most common cancer among men worldwide, with 1.3 million new cases diagnosed in 2020 (Source: International Agency for Research on Cancer).
  • The five-year survival rate for prostate cancer is approximately 92% in the United States (Source: National Cancer Institute).
  • Радиosensitization of CaB34-CF cells by NNMT siRNA resulted in a 2.5-fold increase in radiation-induced cellular senescence (Source: A Novel Primary Cell Line Model of Localized Prostate Cancer and Radioresistance-A Role for Nicotinamide N-Methyltransferase. Cells, 2025,14(11):819).
  • The 3D organoid clonogenic assay in CaB34-CF cells showed a significant decrease in colony formation after treatment with NNMT siRNA (Source: A Novel Primary Cell Line Model of Localized Prostate Cancer and Radioresistance-A Role for Nicotinamide N-Methyltransferase. Cells, 2025,14(11):819).

Sources:

  • A Novel Primary Cell Line Model of Localized Prostate Cancer and Radioresistance-A Role for Nicotinamide N-Methyltransferase. Cells, 2025,14(11):819.
  • International Agency for Research on Cancer. Cancer Today. 2020.
  • National Cancer Institute. Prostate Cancer Statistics. 2020.

Read more